The emergence of therapeutic agents like semaglutide and tirzepatide has transformed the approach to treating type 2 diabetes and supporting weight loss. While both drugs share a shared mechanism of action – mimicking the effects of the natural hormone GLP-1 – tirzepatide possesses a novel advantage: it’s a dual stimulator, targeting both GLP